Ranbaxy
Sun Pharma buyout of Ranbaxy gets conditional US nod
31 Jan 2015
Fearing that the $4-billion deal would be anti-competitive, the FTC has stipulated that Sun sell its interest in a generic anti-bacterial medicine
Sun Pharma, Ranbaxy merger deal gets conditional CCI nod
09 Dec 2014
The CCI has asked the two companies to sell off seven brands with combined sales of less than Rs50 crore and market share of 60 to 80 per cent, which the regulator felt, would adversely affect competition
US court dumps Ranbaxy’s bid to stall launch of rival generics
20 Nov 2014
Ranbaxy’s move is seen as risky especially since the drug maker has been under regulatory probe for a long period now
Ranbaxy sues US FDA over revoking drug approvals
18 Nov 2014
Generic Nexium and Valcyte together would have contributed about $200 million to Ranbaxy's revenue in the first six months of market exclusivity, say analysts
Ranbaxy grilled by US Justice Dept over Medicaid drug pricing
18 Sep 2014
The US Justice Department has requested Ranbaxy for documents and information through a civil investigative demand, though it does not allege any wrongdoing
US judge upholds Ranbaxy-Pfizer Lipitor marketing deal
13 Sep 2014
In a piece of good news for the US FDA-challenged Ranbaxy laboratories, a US court has dismissed an anti-trust suit against Pfizer Inc and India's Ranbaxy that accused them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor
.webp)
